StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) stock

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)

Close on Nov 18, 2026Market cap $7.02BP/E –Yield –

Axsome Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Axsome Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -24.7%. For fiscal 2025 it was -28.7%, against -74.5% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-28.7%+45.8
FY2024Dec 31, 2024-74.5%+13.9
FY2023Dec 31, 2023-88.4%+285.6
FY2022Dec 31, 2022-374.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-23.5%+8.5
Q1 FY2026Mar 31, 2026-33.8%+15.2
Q4 FY2025Dec 31, 2025-14.6%+48.5
Q3 FY2025Sep 30, 2025-27.6%+34.0
Q2 FY2025Jun 30, 2025-32.0%+59.1
Q1 FY2025Mar 31, 2025-48.9%+42.2
Q4 FY2024Dec 31, 2024-63.1%+74.8
Q3 FY2024Sep 30, 2024-61.7%+46.0
Q2 FY2024Jun 30, 2024-91.0%+52.8
Q1 FY2024Mar 31, 2024-91.1%−79.3
Q4 FY2023Dec 31, 2023-137.9%+113.4
Q3 FY2023Sep 30, 2023-107.6%+158.5
Q2 FY2023Jun 30, 2023-143.8%+326.0
Q1 FY2023Mar 31, 2023-11.9%–
Q4 FY2022Dec 31, 2022-251.3%–
Q3 FY2022Sep 30, 2022-266.1%–
Q2 FY2022Jun 30, 2022-469.8%–

More Axsome Therapeutics figures

See a number that looks wrong?